Comparative <i>in vitro</i> activity of sulbactam with avibactam or durlobactam against carbapenem-resistant <i>Acinetobacter baumannii</i>
These data show that imipenem potentiates sulbactam-based combinations to a greater extent than meropenem; however, future studies are needed to define how these data should be applied in clinical practice.
Authors
- Yohei Doi (ORCID: https://orcid.org/0000-0002-9620-2525)
- Ellen G Kline (ORCID: https://orcid.org/0009-0006-7167-6368)
- M. Patrick Griffith (ORCID: https://orcid.org/0000-0003-1012-881X)
- Kevin M Squires (ORCID: https://orcid.org/0009-0007-7818-905X)
- Ryan K. Shields (ORCID: https://orcid.org/0000-0001-9794-5665)
- Ava J Dorazio
Institutions
- Fujita Health University (JP)
- University of Pittsburgh (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1093/jacamr/dlaf098
- Citations
- 2
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.18
Funders
- Pfizer
- GlaxoSmithKline
- Gilead Sciences
- University of Pittsburgh
- Cidara Therapeutics
- Entasis Therapeutics
- Meiji Seika Pharma
- Shionogi
- National Institutes of Health
- Allergan